Skip to main content
. 2018 Feb 23;5(2):91–99. doi: 10.1007/s40801-018-0131-3

Table 4.

Suspect product’s active ingredients with the highest proportion of “drug ineffective” reports in FAERS during the study period (top 25)

Product’s active ingredient Total FAERS reports DI reports % DI
Docosanol 4282 2124 49.6
OnabotulinumtoxinA 13,362 5503 41.2
Fexofenadine hydrochloride 9400 3462 36.8
Bupivacaine hydrochloride 1085 387 35.7
Diphenhydramine citrate/ibuprofen 1326 472 35.6
Hydroxychloroquine sulfate 2335 829 35.5
Oxybutynin 6573 2201 33.5
Loratadine 13,511 4397 32.5
Suvorexant 4009 1298 32.4
Orlistat 3615 1166 32.3
Naproxen sodium 19,349 5975 30.9
Loratadine/pseudoephedrine sulfate 4309 1250 29.0
Dimethicone/loperamide hydrochloride 2849 819 28.7
Fesoterodine fumarate 2186 628 28.7
Fexofenadine/pseudoephedrine 1467 416 28.4
Miconazole nitrate 1016 288 28.3
Amphetamine aspartate/amphetamine sulfate/dextroamphetamine saccharate/dextroamphetamine sulfate 2513 705 28.1
Acetaminophen/aspirin/caffeine 2422 655 27.0
Omeprazole magnesium 4834 1305 27.0
Amphotericin B 1908 502 26.3
Sildenafil citrate 15,302 3985 26.0
Triamcinolone acetonide 4095 1066 26.0
Solifenacin succinate 5688 1440 25.3
Leflunomide 3933 966 24.6
Loperamide hydrochloride 2788 679 24.4

DI drug ineffective, FAERS FDA Adverse Event Reporting System